Table 3.

Frequency and Fisher’s Exact Test of the Distribution of SERT Variants in Subjects with Opioid Dependence (OD) and Control Subjects (HC +NOD)

Genotype	Cases	Controls	Model (Dominant/Recessive)	p	Odds Ratio (95% CI)
A) Promoter tandem repeats
	NOD	HC
LL	53	46	[SS+SL] vs LL	0.31	1.29 (0.782–2.15)
SL	80	49
SS	17	16	SS vs [SL+LL]	0.46	1.32 (0.634–2.74)
B) Promoter tandem repeats
	OD	NOD
LL	55	53	[SS+SL] vs LL	0.48	1.18 (0.744–1.88)
SL	90	80
SS	29	17	SS vs [SL+LL]	0.17	0.639 (0.336–1.22)
C) Promoter tandem repeats)
	OD	HC
LL	55	46	[SS+SL] vs LL	0.091	1.53 (0.934–2.51)
SL	90	49
SS	29	16	SS vs [SL+LL]	0.61	0.84 (0.434–1.63)
D) Promoter tandem repeats
	OD	HC+NOD
LL	55	99	[SS+SL] vs LL	0.176	1.32 (0.88–1.98)
SL	90	129
SS	29	33	SS vs [SL+LL]	0.24	0.74 (0.42–1.24)
E) rs16965628 (intronic SNP)
	OD	HC+NOD
CC	0	1	[CC+CG] vs GG	0.18	1.44 (0.84–2.47)
CG	33	26
GG	234	276	CC vs [CG+GG]	0.35	2.65 (0.11–65.39)
F) rs2066713 (intronic SNP)
	OD	HC+NOD
CC	37	49	[CC+CT] vs TT	0.94	1.01 (0.73–1.41)
CT	133	144
TT	106	122	CC vs [CT+TT]	0.46	1.19 (0.75–1.89)